Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance)Ace J. Hatch, Andrew B. Nixon, Alexander B. Sibley et al.|Cancer Medicine|2016Cited by 20
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Chen Jiang, Daniel L. Bowers, Ace J. Hatch et al.|UNC Libraries|2020Cited by 7
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound HealingJingquan Jia, Andrew B. Nixon, Andrew Dellinger et al.|Clinical Cancer Research|2015Cited by 5
Supplemental Table 2 from Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound HealingJingquan Jia, Andrew B. Nixon, Andrew Dellinger et al.|Unknown|2023Cited by 0
Supplemental Table 1 from Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound HealingJingquan Jia, Andrew B. Nixon, Andrew Dellinger et al.|Unknown|2023Cited by 0